European CHMP approval of Abiraterone (Mylan) for treatment of metastatic prostate cancer
Abiraterone Mylan is a generic, bioequivalent to Zytiga and will be licensed for the same indications.
Source:
European Medicines Agency
Abiraterone Mylan is a generic, bioequivalent to Zytiga and will be licensed for the same indications.
European Medicines Agency